Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $65.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on HALO. Benchmark restated a buy rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They set an outperform rating and a $54.00 price target for the company. Piper Sandler cut shares of Halozyme Therapeutics from an overweight rating to a neutral rating and raised their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. JMP Securities cut their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a market outperform rating for the company in a research note on Wednesday, May 8th. Finally, Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an overweight rating in a research note on Friday, June 7th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of Moderate Buy and an average target price of $57.25.

Halozyme Therapeutics Stock Down 0.7 %

NASDAQ HALO opened at $51.63 on Monday. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. The firm has a 50-day simple moving average of $45.03 and a 200 day simple moving average of $40.38. Halozyme Therapeutics has a twelve month low of $32.83 and a twelve month high of $53.00. The stock has a market cap of $6.57 billion, a PE ratio of 21.33, a PEG ratio of 0.53 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The business had revenue of $195.88 million during the quarter, compared to analysts’ expectations of $201.72 million. On average, research analysts forecast that Halozyme Therapeutics will post 3.66 EPS for the current year.

Insider Activity

In other news, Director Matthew L. Posard sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 109,755 shares in the company, valued at $5,488,847.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders sold 30,000 shares of company stock worth $1,338,800. Insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rise Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $25,000. Whittier Trust Co. acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $27,000. Principal Securities Inc. acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $34,000. Fidelis Capital Partners LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $52,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 293 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.